short review

memo - Magazine of European Medical Oncology

, Volume 5, Issue 2, pp 101-104

First online:

The role of biomarkers in the choice of therapy in breast cancer

  • Brigitte MlineritschAffiliated with3rd Medical Department with Hematology, Medical Oncology, Hemostaseology, Rheumatology and Infectious Diseases, Laboratory of Immunological and Molecular Cancer Research (LIMCR), Center for Clinical Cancer and Immunology Trials, Arbeitsgemeinschaft Medikamentöse Tumortherapie (AGMT), Private Medical University Hospital Salzburg Email author 
  • , Sigrun ResslerAffiliated with3rd Medical Department with Hematology, Medical Oncology, Hemostaseology, Rheumatology and Infectious Diseases, Laboratory of Immunological and Molecular Cancer Research (LIMCR), Center for Clinical Cancer and Immunology Trials, Arbeitsgemeinschaft Medikamentöse Tumortherapie (AGMT), Private Medical University Hospital Salzburg
  • , Richard GreilAffiliated with3rd Medical Department with Hematology, Medical Oncology, Hemostaseology, Rheumatology and Infectious Diseases, Laboratory of Immunological and Molecular Cancer Research (LIMCR), Center for Clinical Cancer and Immunology Trials, Arbeitsgemeinschaft Medikamentöse Tumortherapie (AGMT), Private Medical University Hospital Salzburg

Rent the article at a discount

Rent now

* Final gross prices may vary according to local VAT.

Get Access

Abstract

The discovery of prognostic and predictive biomarkers, enabling the application of more individualized therapies to different molecular breast cancer (BC) subtypes, has already led to changes in BC treatment during the past decades. In this review, the importance of established as well as of emerging biomarkers, currently undergoing testing for technical validity and clinical utility, is discussed.

Keywords

Breast cancer Biomarker Prognostic Predictive